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Abstract. A sensitive and reproducible enzyme-linked immunosorbent assay (ELISA) for the determination of the
concentration of ivermectin (IVM) in biological fluids was developed. A conjugate of IVM on bovine serum albumin
and poly-L-lysine was used to produce antibodies in rabbits and served as a solid-phase marker for titration of
antibodies, respectively. The competitive ELISA was conducted by simultaneously incubating IVM and IVM-biotin
conjugate with anti-IVM antiserum over goat anti-rabbit IgG (Fc) and then determining the amount of bound IVM
biotin with avidin-peroxidase conjugate as a tracer. The coefficient of variation for the assay was less than 10% in
the range of 0.3â€”10 ng/ml. The limit of detection was 0. 1 ng/ml. The cross-reactivities of anti-IVM antiserum with
some anthelmintic drugs were negligible. Using this ELISA, serum levels of IVM were easily determined in Mon
golian jirds (Meriones unguiculatus) up to 72 hr following a single oral dose of 500 p@g/kgof body weight.
Ivermectin (WM), a macrocyclic lactone produced by an
actinomycetes, Streptomyces avermitilis, is a potent new an
tiparasitic agent. It is active at extremely low doses against
a wide variety of nematode and arthropod parasites.' Re
cently, its antiparasitic potency against Onchocerca volvulus,
Wuchereria bancrofti, and Brugia malayi has been tested in
humans.2 Both in terms of clinical efficacy and side effects,
NM is becoming a microfilaricidal agent of first choice.2 As
a prerequisite for studying the pharmacokinetics of IVM in
humans, a method is needed for IVM analysis that is suffi
ciently sensitive to determine the concentration of IVM in
biological fluids. Several high-performance liquid chroma
tography (HPLC) procedures have been reported for deter
mining IVM in plasma.@7 However, HPLC procedures ne
cessitate time-consuming extractions and require a relatively
large amount of blood, and thus are unsuitable for the routine
screening of large numbers of samples or field use. Recently,
Schmidt and others have produced monoclonal antibodies to
IVM and developed an enzyme immunoassay as an alter
native to HPLC for detecting IVM in agricultural and en
vironmental samples.8 However, their assay system was not
applied to the measurement of IVM in biological fluids of
animals. We have investigated this approach further with the
intent of devising a simple, sensitive enzyme-linked immu
nosorbent assay (ELISA) for detection of IVM in the blood
of humans and animals. In this report, we describe 1) the
production of anti-IVM antibodies in the rabbit, 2) the de
velopment of a competitive ELISA, and 3) the preliminary
application of this immunoassay to the study of the phar
macokinetics of IVM in Mongolian jirds (Meriones ungui
culatus).
MATERIALS AND METHODS
Materials. Ivermectin is an approximately 80:20 mixture
of the 22,23-dihyrdoavermectin B,,, and Bib (Figure 1). This
compound was extracted with ether from IvomecÂ®, which
was obtained from Shionogi Pharmaceutical Co., Ltd. (Osa
ka, Japan). Bovine serum albumin (BSA), porcine serum al
bumin (PSA) and poly-L-lysine hydrobromide (molecular
weight = 45,000â€”87,000) were obtained from Sigma Chem
ical Co. (St. Louis, MO). Goat anti-rabbit IgG peroxidase
conjugate and goat anti-rabbit IgG (Fc) were obtained from
Cappel Laboratories (West Chester, PA). Block AceÂ®was
obtained from Dainipon Pharmaceutical Co., Ltd. (Osaka,
Japan). N-(2-aminoethyl) biotinamide was obtained from
Vector Laboratories, Inc. (Burlingame, CA). All other chem
icals or solvents were reagent grade or chemically pure.
Preparation of IVM-BSA conjugate used as an im
munogen. The IVM was first converted to the nitrophenyl
compound and conjugated with BSA as shown in Figure 1.
Ivermectin (74 mg), triethylamine (34 mg), and 4-diethyl
aminopyridine (34 mg) were dissolved in 2 ml of methylene
chloride and cooled to 4Â°C,then 4-nitrophenyl chloroformate
(35 mg) dissolved in 0.5 mi of methylene chloride was added
and stirred for 1 hr at 4Â°C. Two milliliters of water was
added to the above solution. The solution was extracted with
ether, the extract was washed three times with water and
dried over anhydrous sodium sulfate, the solvent was re
moved under vacuum, and the residue was purified by pre
parative thin-layer chromatography (TLC, silica gel 60F254,
20 x 20 cm with a thickness of 0.5 mm; E. Merck, Darm
stadt, Germany) with tetrahydrofuran:chloroform (1 : 10) to
obtain the nitrophenyl. compound (42 mg, 48% yield). The
nitrophenyl compound (12 mg) was dissolved in 0.5 ml pyr
idine and slowly added to a solution of BSA (25 mg) dis
solved in 2.5 ml of 10 mM phosphate buffer (pH 7.4) and
2.0 mi of pyridine at 4Â°C.The mixture was stirred overnight
at room temperature. The resulting BSA conjugate was di
alyzed against 5 liters of 10 mM phosphate buffer, pH 7.4,
(five changes) for three days.
Preparation of 1VM-poly-L-lysine conjugate used as a
solid phase marker. The WM-poly-L-lysine conjugate was
prepared in a three-step procedure as shown in Figure 1. The
5-keto derivative of IVM was prepared according to the pro
cedure of Fisher and Mrozik.9 Manganese dioxide (1.25 g)
was added to a solution of NM (350 mg) dissolved in 9 ml
of methylene chloride and stirred for 3 hr at room temper
ature. The solution was filtered with filter paper and the sol
vent was removed under vacuum. Purification of the residue
by preparative TLC with tetrahydrofuran:chloroform (1:5)
gave 5-keto-IVM (284 mg, 72% yield).
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FIGuRe 1. Preparation of the ivermectinâ€”bovine serum albumin
conjugate used as a solid-phase marker.
Preparation of IVM oxime from the 5-keto IVM was car
ried out using the procedure of Zhang and others.'Â° In a
typical experiment, a mixture of 5-keto IVM (180 mg), car
boxymethoxylamine hemihydrochloride (30 mg), and sodi
um acetate (1 1 mg) were dissolved in 3 ml of a solution of
methanol:water (9: 1) and stirred overnight at room temper
ature. The solvent was removed under vacuum and chloro
form was added. The chloroform layer was washed three
times with water and dried over anhydrous sodium sulfate
and then concentrated to give DIM oxime (50 mg, 58%
yield).
The IVM oxime was conjugated to poly-L-lysine by the
modification of a method of Liu and others.â€• l-ethyl-3 (3-
dimethylaminopropyl) carbodiimide hydrochloride (1 mg)
and N-hydroxysuccinimide (1 mg) were added to the solu
tion of IVM oxime (5 mg) dissolved in 0.2 ml of dimethyl
formamide (DMF), and then stirred for 30 mm at room tem
perature. This solution was slowly added to poly-L-lysine
hydrobromide (5 mg) dissolved in 0.25 ml of 0. 13 M
NaHCO3 and stirred for 1.5 hr at room temperature. The
resulting conjugate was dialyzed against 3 liters of 0. 1 M
NaHCO3 for two days. The solution of conjugate was ad
justed to pH 5.5 with 1 N HC1 and centrifuged at 2,500 rpm
for 30 mm. The supernate was used as a solid-phase marker.
Preparation of IVM-blotin conjugate. The IVM-biotin








(IVM-BSA) conjugate used as the immunogen and NM-poly-L-lysine
ten method of Liu and others (Figure 2). â€˜â€Ĩvermectin oxime
(1.5 mg), N-hydroxysuccinintide (0.2 mg), and dicyclohexyl
carbodiimide (0.35 mg) were dissolved in 50 pAof DMF and
incubated for 1 hr at room temperature. The mixture was
added to a solution of N-(2-aminoethyl)biotinamide (0.7 mg)
and triethylamin (3 pA) in 200 p.1 of DMF, stirred for two
days at room temperature, and applied to a preparative TLC
plate. The plate was developed in chloroform-methanol (3:
1). The IVM-biotin conjugate had an Rf value of 0.58 and
was dissolved in 1 ml of DMF and stored at â€”30Â°C(stock
IVM-biotin solution).
Immunization. A rabbit was injected both intradermally
and intramuscularly with the IVM-BSA conjugate (I mg)
dissolved in 1 ml of saline and emulsified with 1 ml of
Freund's complete adjuvant at sites on a shaved back area.
For booster injection, the IVM-BSA conjugate (0.5 mg) in
0.5 ml of saline and 0.5 ml of Freund's incomplete adjuvant
was used. The repeated boosters were given on weeks 2, 4,
6, and 8 after the initial injection. Blood samples were drawn
via a marginal ear vein before immunization and 2, 4, 8, and
12 weeks after initial injection with the LVM-BSA conjugate.
The serum was stored at â€”30Â°Cuntil use.
Antibody titration by indirect ELISA. An indirect ELI
SA was used to detect antibodies. Wells of 96-well microtiter
plates (#655070; Dynatech Laboratories Inc., Chantilly, VA)
were coated overnight at room temperature with 200 p.1 of
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FIGuRE2. Preparation of the ivermectin (IVM)â€”biotinconjugate.
IVM-poly-L-lysine conjugate (0.75 p@g/mlin 0.1 M sodium
bicarbonate buffer, pH 9.6). The wells were washed three
times with 300 pA of phosphate-buffered saline (PBS, 10
mM Na@HPO4,150 mM NaC1, pH 7.4) containing 0.05% [v/
v] Tween 20 (PBS-Tween). They were then blocked with
300 pi of Block AceÂ®diluted 1:5 in distilled water for 40
mm at 37Â°Cto prevent nonspecific absorption and washed
two times with 300 p.1of PBS-Tween. Wells were incubated
for 1 hr at 37Â°Cwith 100 p.1 of rabbit anti-NM antiserum
diluted serially in 0.1% BSA, PBS-Tween and 100 @lof 1%
PSA in 10 mM phosphate buffer. The wells were washed
five times with 300 p.1 of PBS-Tween, incubated with 200
pA of goat anti-rabbit IgG peroxidase conjugate diluted 1:
1,500 in 0.1% BSA, PBS-Tween for 1 hr at room tempera
tune, washed three times with PBS-Tween, and incubated for
30 ruin at room temperature with 200 p.1of substrate solution
(80 mM citrate phosphate buffer, pH 5.0, 4.4 mM 1,2-phen
ylene diamine, and 2 mM hydrogen peroxide). The reaction
was terminated by the addition of 100 pA of 0.2 M sulfuric
acid, and the absorbance at 492 nm was measured spectro
photometrically using an ELISA analyzer (Model ETY-96;
Toyosoki Co. Ltd., Kanagawa, Japan).
Indirect competitive ELISA using IgG-peroxidase con
jugate. The indirect competitive ELISA was identical to the
antibody titration procedure except that 100 p.1of sample or
NM dissolved in 10% (v/v) methanol in 1% PSA, PBS
Tween were simultaneously incubated for 2 hr at 37Â°Cwith
100 pAof anti-NM antiserum diluted 1:2,000 in 0.1% BSA,
10 mM phosphate buffer. Bound antibody was measured as
described in the antibody titration.
Competitive ELISA using IVM-biotin conjugate and
avidln-peroxidase conjugate. Wells of 96-well microtiter
plates (Nunc Immuno@ Plate MaxiSorp; Nunc, Roskilde,
Denmark) were coated with 200 pA of goat anti-rabbit IgG
(Fc), (3.5 mg/L in 0.1 M sodium bicarbonate buffer, pH 9.6)
for 2 hr at 37Â°C.The antiserum solution was removed and
remaining binding sites were blocked by adding to each well
300 p1 of a 10 g/L BSA solution in distilled water containing
8)
FIGuRE3. Standard curve of the competitive enzyme-linked im
munosorbent assay for ivermectin (NM). 0 = using IgG peroxidase
conjugate; . = using NM-biotin conjugate and avidin peroxidase
conjugate. Each point is the mean of four determinations.
0.5 g of sodium azide per liter. After each well was washed
with 300 p.1 of PBS-Tween, 100 @tlof a standard of IVM or
a blood sample diluted in 10 mM phosphate buffer (pH 7.4)
containing 0. 1% BSA (phosphate buffer-BSA), 50 p.1 of a 1:
2,000,000 dilution of IVM-biotin stock in phosphate buffer
BSA, and 50 pAof a 1:20,000 dilution of anti-IVM antiserum
in phosphate buffer-BSA were added to each well and the
incubation was continued overnight at room temperature.
The wells were washed three times with 300 p.1of PBS
Tween and reacted with 200 p.1 of avidin-peroxidase diluted
1:7,000 in PBS-1\veen for 1 hr at room temperature. The
wells were then washed four times with 300 p.1 of PBS
Tween. To each well, 200 p.1 of the substrate solution (pH
4.0) containing 2.5 mM 2,2'-azino-di-(3-ethylbenzthiazoline
6-sulfonic acid) diammonium salt, 5.0 mM H2O2, 300 mM
citric acid, and 51 mM disodium hydrogen phosphate per
liter was added, and the color was allowed to develop in the
dark for 40 mm at room temperature. One hundred microl
iters of sodium azide (1 g/L in distilled water) was added to
terminate the enzymatic reaction, and absorbances were
measured at 405 nm with a microplate reader (MultiskanÂ®
BICHROMATIC; Labsystems, Helsinki, Finland).
Detennination of IVM concentrations in biological flu
ids from a standard curve. A standard curve was con
structed in every experiment in a range of 0.03â€”30 ng/mi. It
showed the percent maximal absorbance on the y-axis and
the concentration of DIM on the x-axis. When the percent
absorbance of sample to be tested was within the working
range of the standard curve, the concentration of IVM in the
sample was determined.
Determination of serum concentrations of IVM in
jirds. Ivermectin was diluted 1:100 in ethanol:saline (1:3 [v/
v]). Four male jirds weighing 104â€”106g were given a single
oral dose of NM at 500 p@g/kgof body weight. Blood from
the retro-orbital sinus (20 pA) was collected into tubes at 0,
1, 2, 3, 6, 12, 24, and 72 hr after administration of NM.
Blood was allowed to clot overnight at 4Â°Cand then centri


















































Values are the mean Â± SD.
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Cross-reactivity of antiâ€”ivermectin(IVM) antiserum with IVM-re
lated compounds and anthelmintics
formed using the WM-biotin and avidin-peroxidase conju
gates.
Specificity. To ascertain the specificity of the rabbit anti
IVM antiserum, the ability of the NM derivative and some
anthelminthic drugs to compete in the competitive ELISA
was evaluated. The degree of cross-reaction of the test com
pounds with anti-IVM antiserum in terms of the percentage
relative activity is shown in Table 1. The relative activity
was expressed as the amount of IVM to produce 50% bind
ing of antibodies and IVM-biotin conjugate X 100/the
amount of test compounds to produce 50% binding of anti
bodies and NM-biotin conjugate. The cross-reactivity of
IVM oxime, a derivative of NM, was 30.9%, but those of
all other drugs tested were less than 0.1%.
Assay precision. The assay precision was examined at
five different NM levels over the range 0.1â€”10ng/ml (Table
2). The recoveries of NM added were satisfactory, and the
coefficient of within assay variation was low. Therefore, the
detection limit of the competitive ELISA using IVM-biotin
and avidin-peroxidase conjugate is 0.1 ng/mi.
Application of the method to biological samples. The
present enzyme immunoassay was applied to monitor the
serum concentration of NM after a single oral dose (500
@.Lg/kgof body weight) to male jirds. Figure 4 shows the
mean serum concentration-time profile of NM after admin
istration. The maximum serum concentration of 43.8 ng/ml
was attained 2 hr after administration. Thereafter, the serum
level rapidly decreased, but interestingly, it again showed
the high value 24 hr after administration.
DISCUSSION
Ivermectin-protein conjugates have been formed and used
as immunizing and screening antigen for the determination
of IVM in biological fluids.8 We report here the successful
preparation of NM-BSA conjugates and production of an
tibodies to NM in the rabbit. The immunogenicity of NM
protein conjugates and the specificity of an antiserum for
NM are markedly influenced by the sites of the NM mol
ecule that are derivatized to couple with the carrier protein.
In our study, the site of coupling of NM with BSA was not
defined exactly. However, the most probable site of coupling
is at the C-S position because the hydroxyl group of the
allylic position is generally more reactive than the hydroxyl
group at the Câ€•-4position.
fuged at 2,000 rpm for 15 mm. The serum was separated
and stored at â€”30Â°Cuntil assayed. The pooled normal jird
serum diluted 1:100 in phosphate buffer-BSA containing
various concentrations of IVM was used for the construction
of a standard curve for the determination of the NM con
centration in jird serum. The serum samples to be measured
were first diluted 1: 100 in phosphate buffer-BSA, and the
concentration of IVM in the samples was then measured by
the competitive ELISA using IVM-biotin.
RESULTS
Production of antibodies against IVM. An indirect ELI
SA was used to monitor the production of IVM antibodies
in the rabbit. The serum samples taken at 6â€”12weeks had
a titer greater than 10,000. The highest titer was detected at
week 8. Repeated booster injections after week 8 did not
significantly increase IVM titers. Therefore, in the subse
quent experiments, serum samples taken eight weeks after
the initial immunization were used.
Competitive indirect ELISA using IgG-peroxidase con
jugate. A typical IVM competitive ELISA dose-response
curve is shown in Figure 3. The dose response range for this
curve is between 10 and 1,000 ng/ml.
Competitive ELISA using IVM-biotin and avidin-per
oxidase conjugate. A typical IVM competitive ELISA dose
response curve is shown in Figure 3. The dose-response
range for this curve is between 0. 1 and 10 ng/ml. The sen
sitivity of the competitive ELISA using the IVM-biotin and
avidin-peroxidase conjugates is 100 times as high as that of
the ELISA using the IgG-peroxidase conjugate. Therefore,
in subsequent experiments, the competitive ELISA was per
T@nu@2
Precision of competitive enzyme-linked immunosorbent assay using ivermectin (IVM)â€”biotinconjugate and avidin-peroxidase conjugate
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serum. This assay should be applicable to any other biolog
ical fluids.
Recently, a Brugia pahangi-jird model has been widely
used for primary screening of anti-filarial drugs.2 However,
no pharmacokinetic study of NM in jirds has been done.
Therefore, we attempted to measure NM concentration in
these animals. Our method successfully determined the se
rum concentration-time profiles of IVM in jirds up to 72 hr
after administration of NM. The serum concentration-time
profiles of our pilot study, however, are different from those
reported by Schnitzerling and Nolan,3 Kojima and Yama
moto,4 and Krishna and Klotz.@ They reported a monoex
ponential decrease in the plasma level of IVM following the
peak concentrations in cows, dogs, and humans. There are
three possible explanations for the appearance of two peaks
after oral administration of NM to jirds. First, NM is in
soluble in water. Therefore, there was considerable variation
in the absorption of NM in the intestine of the jirds. If this
was the case, the individual variation in the peak time after
oral administration should be more prominent. Second, NM
is metabolized to products that influence the assay system.
This is also very unlikely because the anti-NM antibodies
we used are relatively specific for IVM and NM is reported
to be excreted mainly in the feces in an unchanged form.'
Third, IVM undergoes enterohepatic circulation (EHC).
Drugs that undergo EHC, e.g., the steroids, show two peaks
in the serum concentration-time profiles that are similar to
the two peaks observed in this study.'3 Interestingly, EHC
of NM in the salmon has been reported,'4 and Edwards and
others reported that IVM was excreted into the bile in mice.'5
Thus, the third explanation is not unlikely. Further studies
will be needed to explain the appearance of two peaks in
concentration-time profile of NM in jirds.
The concentration of IVM in the blood has been deter
mined by HPLC. However, HPLC procedures are time-con
suming, require large amounts of blood, and are unsuitable
for routine screening of large numbers of samples or field
use. We have developed a simple, sensitive, and reproducible
competitive ELISA for the determination of NM in biolog
ical fluids. Our method requires only 5 pA of serum for trip
licate determinations with a detection limit of 10 ng/ml in
serum. This assay can be used for monitoring plasma levels
of IVM in clinical studies for evaluating its optimal dosage
regimen and pharmacokinetics of IVM in humans and cx
perimental animals.
Financial support: This work was partially supported by grants-in
aid (no. 04557023 and no. 06770188) for Scientific Research from
the Ministry of Education, Science and Culture of Japan.
Authors' addresses: Yoshinori Mitsui, Yasunoni Fujimaki, and Yosh
iki Aoki, Department of Parasitology, Institute of Tropical Medicine,
Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852, Japan. Hi
deaki Tanimoni and Tsunehiro Kitagawa, Faculty of Pharmaceutical
Sciences, Nagasaki University, 1-14 Bunkyoumachi, Nagasaki 852,
Japan.
Reprint requests: Yoshinori Mitsui, Department of Parasitology, In
stitute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto,
Nagasaki 852, Japan.
REFERENCES
I . Campell WC, Fisher MH, Stapley EO, Albers-Schonberg G, Ja










FIGURE 4 Serum concentration of ivermectin (IVM) in jirds fol
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sents the mean Â±SE for five animals.
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